Updated Review of Current Therapeutic Approaches for the Management of Sickle Cell Disease

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Sickle cell disease (SCD) is a severe inherited blood disorder causing abnormal hemoglobin (HbS) and sickle-shaped red blood cells.
• SCD leads to blocked blood flow, increasing risks of infection, anemia, pain crises, and organ damage.
• The disease disproportionately affects Black populations, with approximately 100,000 Americans impacted, including 40,000 children.

Purpose of the Study:

• To provide a comprehensive overview of current and emerging therapeutic approaches for sickle cell disease.
• To emphasize the mechanisms, efficacy, and clinical implications of various SCD treatments.
• To highlight ongoing research aimed at enhancing treatment options and finding potential cures for SCD.

Main Methods:

• Review of existing literature on Food and Drug Administration (FDA)-approved drugs for SCD.
• Analysis of clinical trial results for L-glutamine, crizanlizumab-TMCA, and voxelotor.
• Exploration of novel therapies including gene therapy, CRISPR-Cas9, stem cell, and bone marrow transplants.

Main Results:

• Six FDA-approved drugs (hydroxyurea, L-glutamine, crizanlizumab-TMCA, voxelotor, Casgevy, Lyfgenia) are available for SCD prophylaxis and treatment.
• L-glutamine and crizanlizumab-TMCA reduce sickle cell crisis episodes by preventing cell damage and sickling.
• Voxelotor enhances hemoglobin's oxygen-binding capacity in SCD patients.

Conclusions:

• Current treatments focus on symptom management, with newer drugs offering specific benefits like crisis reduction and improved oxygen transport.
• Innovative therapies like gene editing and transplants hold promise for genetic correction and potential cures, though challenges remain.
• Continued research is crucial for advancing SCD treatment and achieving eradication of the disease.